© 2017 MEDYSSEY USA, INC. CREATED BY EMERSA CREATIVE

MEDYSSEY USA, INC.

HEADQUARTERS

1550 E. Higgins Road . Suite #123

Elk Grove Village . IL . 60077 . USA

P ::  (847) 427-0200
F ::  (888) 518-9070

 129, Hanbang expo-ro . Jecheon-si
Chungcheongbuk-do . Republic of Korea
P ::  (+82) 43-716-1014
F ::  (+82) 43-716-1015

IBT ::  (+82) 31-879-0414 **
** English communication available

medyssey.co.kr
 

UPCOMING EVENTS

USA EXHIBITS
INTERNATIONAL EXHIBITS

May 12, 2018

WSE 2018

Vietnam

September 19, 2018

Barcelona, Spain

Please reload

March 07, 2018

New Orleans, LA

July 05, 2018

Napa, CA

July 11, 2018

Los Angeles, CA

September 27, 2018

Los Angeles, CA

December 06, 2018

Scottsdale, Arizona

Please reload

February 23, 2017

Interspinous spacers sometimes also called as Interspinous process decompression systems, are the devices implanted between vertebral spinous processes. These spacers are made up of a very strong but lightweight metal (titanium) which is biocompatible in the human body. These devices are imbedded in body to confine painful motion else enabling normal motion and to treat lumbar spinal stenosis, discogenic low-back pain, facet syndrome, disc herniations, and non-traumatic instability.

July 23, 2015

As we continue to see how 3D printing is being used by more medical professionals to create study models prior to a surgery, we’re also starting to see an increase in the amount of 3D prints that are designed to be implanted into the human body, too.  

 

More recently, a South Korean medical team used 3D printing to manufacture a patient-specific custom pelvis implant for a teenage girl who needed a replacement after suffering from bone cancer. 

August 27, 2010

Medyssey, a South Korea-based spinal implant manufacturer, received FDA 510k clearance for the Zenius Thoracolumbar Spinal System in titanium alloy, used for treating deformity and degenerative spinal pathologies, according to a company news release. 

August 26, 2010

Corin reported 1H:10 revenues of GBP 21.9 million ($33.0 million), up 6% over the year-ago period. The company attributed sales momentum to the Trinity hip system and the LARS ligament augmentation system in the Australian market. Growth rates exclude the effects of currency. EPS for 1H:10 was GBP 0.56 ($0.84), which compares to a loss per share of GBP 0.16 ($0.26) in 1H:09.

Please reload

 
 

IN THE NEWS